Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial

Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial

Introduction Women-controlled HIV prevention technologies that overcome adherence challenges of available daily oral pre-exposure prophylaxis and give women a choice of options are urgently needed. Broadly neutralising monoclonal antibodies (bnAbs) administered passively may offer a valuable non-ant...

Full description

Bibliographic Details
Main Authors: Nigel Garrett, Farzana Osman, Sharana Mahomed, Edmund Capparelli, Nonhlanhla Yende Zuma, Derseree Archary, Penny Moore, Natasha Samsunder, Lynn Morris, Salim Abdool Karim, Catherine Hankins, Carolyn Williamson, Bruno Pozzetto, Kevin Carlton, Richard A Koup, Quarraisha Abdool Karim, Leila Mansoor, Tanuja Narayansamy Gengiah, Ishana Harkoo, Precious Radebe, Izukanji T Sikazwe, Disebo Potloane, Nqobile Myeni, Lucio Gama, Sandeep Narpala, Leonid Serebryannyy, Nicole Doria-Rose
Format: Article
Language:English
Published: BMJ Publishing Group 2023-08-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/13/8/e076843.full

Internet

https://bmjopen.bmj.com/content/13/8/e076843.full

Similar Items